News
ABCL
11.06
+1.52%
0.17
FDA names acting heads of drug and vaccine units to permanent roles
Seeking Alpha · 6d ago
Weekly Report: what happened at ABCL last week (0831-0904)?
Weekly Report · 09/07 09:07
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Medtronic (MDT) and AbCellera Biologics (ABCL)
TipRanks · 09/02 11:30
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 09/01 14:15
Weekly Report: what happened at ABCL last week (0824-0828)?
Weekly Report · 08/31 09:08
What'sGoing On With AbCellera Biologics Stock On Tuesday?
Benzinga · 08/25 18:38
HHS said to be eyeing two new FDA deputy commissioners for technology and drugs
Seeking Alpha · 08/25 17:53
AbCellera rises 10.7%
TipRanks · 08/25 14:06
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Benzinga · 08/25 14:03
Major Insider Move Signals Growing Confidence in AbCellera Biologics
TipRanks · 08/25 02:08
Weekly Report: what happened at ABCL last week (0817-0821)?
Weekly Report · 08/24 09:08
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain?
Simply Wall St · 08/20 02:25
AbCellera Biologics call volume above normal and directionally bullish
TipRanks · 08/19 19:50
Twist Bio jumps sending AI-linked peers higher after Anthropic announcement
Seeking Alpha · 08/19 14:58
Insider Confidence Surge: Director Makes Bold Move on AbCellera Biologics
TipRanks · 08/19 02:01
Largest borrow rate increases among liquid names
TipRanks · 08/18 12:45
AbCellera Biologics (ABCL) Gets a Buy from BMO Capital
TipRanks · 08/18 11:37
Monday 8/17 Insider Buying Report: ABCL, BPRN
NASDAQ · 08/17 17:52
Weekly Report: what happened at ABCL last week (0810-0814)?
Weekly Report · 08/17 09:08
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Seeking Alpha · 08/17 02:54
More
Webull provides a variety of real-time ABCL stock news. You can receive the latest news about Abcellera Biologics Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.